health
ByteDance's Anew Labs Presents First AI-Designed Therapy as TikTok Parent Enters Drug Discovery Race
ByteDance’s drug discovery unit Anew Labs presented its first AI-designed therapy at a major immunology conference in Boston, showing a generative-AI-designed small molecule targeting IL-17, a protein-protein interaction long considered undruggable.
TL;DR
- Anew Labs, ByteDance's drug discovery unit, presented its first AI-designed therapy targeting IL-17 at an immunology conference in Boston.
- The therapy is a small molecule designed to inhibit IL-17, a protein-protein interaction previously deemed undruggable by conventional methods.
- Anew Labs also introduced AnewOmni, a generative AI framework trained on millions of biomolecular complexes, designed to create functional molecules across different scales.
- ByteDance's entry into AI drug discovery aligns them with other tech companies like Isomorphic Labs, Anthropic, and Insilico Medicine.
- The unit aims to develop oral small molecule therapies as alternatives to expensive injectable antibody treatments for autoimmune diseases.
- AnewOmni's ability to design across scales is presented as a unique advantage, potentially overcoming limitations faced by competitors.
- The company's drug discovery efforts leverage AI infrastructure developed for TikTok's recommendation algorithm, focusing on processing vast data to predict biological responses.
- While promising preclinical data has been shown, the ultimate success of AI in revolutionizing drug development, and Anew Labs' role in it, will depend on clinical trial outcomes.